Pharmaceuticals Industry Deals and Trends in January 2021 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)

GlobalData's "Pharmaceuticals Industry Deals and Trends in January 2021 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2021. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market.

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

2 Pharmaceuticals & Healthcare, Global, Deal Summary, 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2021 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, January 2021 12

2.2.1 Novartis Enters into Licensing Agreement with BeiGene 12

2.2.2 Nordic Capital to Acquire Advanz Pharma 13

2.2.3 Artiva Biotherapeutics Enters into Licensing Agreement with Merck 13

2.2.4 Loxo Oncology and Merus to Enter into Licensing Agreement 14

2.2.5 Sanofi to Acquire Kymab 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, January 2021 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, January 2021 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, January 2021 17

3.1.1 Top M&A Deals in January 2021 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2020- January 2021 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2021 20

3.2.1 Top Equity Offering Deals in January 2021 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2020- January 2021 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2021 23

3.3.1 Top PE/VC Deals in January 2021 24

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2021 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, January 2021 26

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2020-January 2021 28

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2020-January 2021 29

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2021 30

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, August 2020- January 2021 31

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), January 2021 32

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, January 2021 33

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2020- January 2021 34

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, August 2020- January 2021 35

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), August 2020- January 2021 36

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2020- January 2021 37

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2021 38

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2021 38

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2021 39

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), August 2020- January 2021 40

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), August 2020- January 2021 41

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), August 2020- January 2021 42

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), August 2020- January 2021 45

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, January 2021 46

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, January 2021 46

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, January 2021 47

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 48

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, January 2021 48

5.1.1 Oncology – Deals of the Month 49

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, January 2021 51

5.2.1 Central Nervous System – Deals of the Month 52

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, January 2021 54

5.3.1 Infectious Diseases – Deals of the Month 55

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, January 2021 57

5.4.1 Cardiovascular – Deals of the Month 58

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, January 2021 59

5.5.1 Immunology – Deal of the Month 60

5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, January 2021 62

5.6.1 Metabolic- Deals of the Month 63

5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, January 2021 65

5.7.1 Gastrointestinal – Deals of the Month 66

6 Deal Summary by Geography 67

6.1 Pharmaceuticals & Healthcare, North America Deals, January 2021 67

6.1.1 North America – Deals of the Month 68

6.2 Pharmaceuticals & Healthcare, Europe, Deals, January 2021 70

6.2.1 Europe – Deals of the Month 71

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, January 2021 73

6.3.1 Asia-Pacific – Deals of the Month 74

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, January 2021 76

6.4.1 Rest of the World – Deals of the Month 77

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 79

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, August 2020- January 2021 79

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, August 2020- January 2021 80

8 Further Information 81

8.1 Methodology 81

8.2 About GlobalData 82

8.3 Contact Us 82

8.4 Disclosure information 82

8.5 Disclaimer 83

List of Tables

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, January 2021 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), January 2021 16

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, January 2021 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2020- January 2021 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, January 2021 21

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 22

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 24

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, January 2021 24

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, August 2020- January 2021 26

Table 13:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), January 2021 27

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2020- January 2021 28

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2020- January 2021 29

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2020- January 2021 30

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2020- January 2021 31

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2020- January 2021 32

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), January 2021 33

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2020- January 2021 34

Table 21:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2020- January 2021 36

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), August 2020- January 2021 37

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 38

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), August 2020- January 2021 39

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2020- January 2021 40

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), January 2021 41

Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, August 2020- January 2021 43

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2021 45

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, January 2021 46

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, January 2021 46

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, January 2021 47

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 49

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 52

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 55

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 58

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 60

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 63

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 66

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 68

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 71

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 74

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 77

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2020- January 2021 79

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2020- January 2021 80

List of Figures

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), August 2020- January 2021 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), January 2021 15

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), January 2021 16

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), August 2020- January 2021 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2020- January 2021 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), August 2020- January 2021 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2020- January 2021 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), August 2020- January 2021 23

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2020- January 2021 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), January 2021 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), January 2021 27

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2020- January 2021 28

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2020- January 2021 30

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2020- January 2021 31

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2020- January 2021 32

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2020- January 2021 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2020- January 2021 35

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2020- January 2021 36

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2020- January 2021 37

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), August 2020- January 2021 38

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2020- January 2021 39

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2020- January 2021 40

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2020- January 2021 41

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, August 2020- January 2021 42

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), August 2020- January 2021 43

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2021 45

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), August 2020- January 2021 48

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), August 2020- January 2021 51

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), August 2020- January 2021 54

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), August 2020- January 2021 57

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), August 2020- January 2021 59

Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 62

Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2020- January 2021 65

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), August 2020- January 2021 67

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), August 2020- January 2021 70

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), August 2020- January 2021 73

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), August 2020- January 2021 76

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2020- January 2021 79

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2020- January 2021 80

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports